A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2011
10/27/2011	US20110262451 Modulators of isovaleryl-coenzyme a dehydrogenase in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoea
10/27/2011	US20110262450 Modulators of monoglyceride lipase in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoea
10/27/2011	US20110262449 Method for the treatment of gout or pseudogout
10/27/2011	US20110262448 Human antibodies that bind mesothelin, and uses thereof
10/27/2011	US20110262447 Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
10/27/2011	US20110262446 Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
10/27/2011	US20110262445 Anti-il-12/il-23 antibodies
10/27/2011	US20110262444 Form-specific antibodies for nag-1 (mic-1, gdf-15), h6d and other tgf-beta subfamily and heart disease and cancer diagnoses
10/27/2011	US20110262443 Epitopes Of Il-17a And Il-17f And Antibodies Specific Thereto
10/27/2011	US20110262442 Compositions for treating cns disorders
10/27/2011	US20110262441 Method for selective control of helper t cell function
10/27/2011	US20110262440 Treatment of pediatric acute lymphoblastic leukemia
10/27/2011	US20110262439 Bispecific single chain antibodies with specificity for high molecular weight target antigens
10/27/2011	US20110262438 Biological materials related to cxcr7
10/27/2011	US20110262437 Use of erbb4 as a prognostic and therapeutic marker for melanoma
10/27/2011	US20110262436 Treatment method
10/27/2011	US20110262435 Il-13 binding agents
10/27/2011	US20110262434 Methods to Expand the Eligible Patient Population for HER2-Directed Targeted Therapies
10/27/2011	US20110262433 Method for inhibiting bone resorption
10/27/2011	US20110262432 mutated netrin 4 proteins, fragments thereof and their uses as drugs
10/27/2011	US20110262431 Pharmaceutical composition comprising antibody composition which specifically binds to ccr4
10/27/2011	US20110262430 Novel antibodies
10/27/2011	US20110262429 Human timp-1 antibodies
10/27/2011	US20110262428 Treating cancer by modulating rna helicases
10/27/2011	US20110262427 Amino acid sequences that modulate the interaction between cells of the immune system
10/27/2011	US20110262426 Methods and kits used in identifying glioblastoma
10/27/2011	US20110262425 Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
10/27/2011	US20110262397 Compounds, compositions, and methods for control of hepatitis c viral infections
10/27/2011	US20110262396 Combination treatments comprising protease binding proteins for inflammatory disorders
10/27/2011	US20110262394 Dna constructs eliciting immune response against flavivirus and effective adjuvants
10/27/2011	US20110262389 Tumor-derived Biological Antigen Presenting Particles
10/27/2011	US20110262388 Novel inhibitors
10/27/2011	US20110262386 Methods of treating inflammation
10/27/2011	US20110262361 effective new drug target for the treatment of tuberculosis
10/27/2011	US20110262358 Molecular marker for cancer stem cell
10/27/2011	US20110262350 Breast endothelial cell expression patterns
10/27/2011	US20110262349 Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma
10/27/2011	US20110262348 Selective targeting of intratumoral cells
10/27/2011	CA2796633A1 Production of heteromultimeric proteins
10/27/2011	CA2794556A1 Novel allergen
10/27/2011	CA2789071A1 Antibodies against human csf-1r and uses thereof
10/26/2011	EP2380976A1 Human anti-human influenza virus antibody
10/26/2011	EP2380913A1 Novel anti-IGF-IR antibodies and uses thereof
10/26/2011	EP2380912A1 Novel anti-IGF-IR antibodies and uses thereof
10/26/2011	EP2380911A1 Antigen binding molecules with increased Fc receptor binding affinity and effector function
10/26/2011	EP2380910A1 Antigen binding molecules with increased Fc receptor binding affinity and effector function
10/26/2011	EP2380908A1 Hepatocyte growth factor (hgf) binding proteins
10/26/2011	EP2380903A1 Differential in tumour gene products and use of same
10/26/2011	EP2380633A1 Use of IL-21 in cancer
10/26/2011	EP2380592A2 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
10/26/2011	EP2380591A2 Vaccine peptide combinations against cat allergy
10/26/2011	EP2380590A2 Improved tuberculosis vaccines
10/26/2011	EP2380589A2 Improved tuberculosis vaccines
10/26/2011	EP2380588A1 Therapeutic Vaccine
10/26/2011	EP2380585A1 Methods of treating autoimmune diseases
10/26/2011	EP2380584A1 Immunostimulatory method
10/26/2011	EP2380558A1 Arranging interaction and back pressure chambers for microfluidization
10/26/2011	EP2380440A1 Regulated attenuation of live vaccines to enhance cross protective immunogenicity
10/26/2011	EP2379600A1 Antibodies against tissue factor pathway inhibitor
10/26/2011	EP2379598A1 Anti-kir3d antibodies
10/26/2011	EP2379596A1 Targeted binding agents directed to 5 1 and uses therefor
10/26/2011	EP2379595A2 Targeted binding agents directed to 5 1 and uses thereof
10/26/2011	EP2379593A2 Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
10/26/2011	EP2379592A1 Antibodies against human angiopoietin 2
10/26/2011	EP2379591A1 Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
10/26/2011	EP2379590A1 Anti-herpes simplex virus antibodies and methods of use thereof
10/26/2011	EP2379109A1 Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature
10/26/2011	EP2379108A1 Immunoglobulin purification
10/26/2011	EP2379107A1 Ljungan virus with improved replication characteristics
10/26/2011	EP2379106A1 Chlamydia antigens and uses thereof
10/26/2011	EP2379105A1 Vaccine
10/26/2011	EP2379104A1 Injectable botulinum toxin formulations
10/26/2011	EP2379103A1 Immunogenic composition and use thereof
10/26/2011	EP2379102A1 Fibcd1 for the prevention and treatment of diseases
10/26/2011	EP2046835B1 Antibodies to il-17a
10/26/2011	EP1996626B1 Anti-idiotypic antibody which neutralizes the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii
10/26/2011	EP1912674B1 Bispecific single chain fv antibody molecules and methods of use thereof
10/26/2011	EP1910410B1 Tuberculosis antigen detection assays and vaccines
10/26/2011	EP1848462B1 Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9
10/26/2011	EP1729806B1 Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
10/26/2011	EP1723170B1 A canine vaccine for protection against ehrlichiosis
10/26/2011	EP1617867B1 Immunomodulating composition comprising a particulate fraction of bacterial mechanical lysates
10/26/2011	EP1602360B1 Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof
10/26/2011	EP1575509B1 Epha2 agonistic monoclonal antibodies and methods of use thereof
10/26/2011	EP1469310B1 Diagnostic for scleroderma
10/26/2011	EP1409748B1 Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof.
10/26/2011	EP1292321B1 Method to increase class i presentation of exogenous antigens by human dendritic cells
10/26/2011	EP1060247B2 Ox-40 receptor binding agent for use in methods for enhancing tumour antigen-specific immune response
10/26/2011	EP0787191B2 Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens
10/26/2011	CN102227446A Anti-cmet antibody
10/26/2011	CN102227442A Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof
10/26/2011	CN102227237A Host cell kinases as targets for antiviral therapies against hcv infection
10/26/2011	CN102227226A Anti-igf antibodies
10/26/2011	CN102227214A Compositions with reduced dimer formation
10/26/2011	CN102225200A Methods and compositions for modulating TWEAK and FN14 activity
10/26/2011	CN102225199A Detoxification technology after absorption of tetanus vaccine
10/26/2011	CN101869590B Chinese medicinal herba epimedii and propolis flavone immunopotentiator
10/26/2011	CN101851291B Heavy chain and light chain variable regions of anti-human BAFF monoclonal antibody
10/26/2011	CN101838311B Mimic short peptide 7B of endothelial cell growth factor VEGF antigen epitope and application thereof
10/26/2011	CN101638440B Heterogenetic antigen-Fc fusion protein capable of inducing antitumor immunity of organism and application thereof

1 ... 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 ... 1823